English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Abstract   Introduction  Magnesium sulfate is used world‐wide to treat pregnant women at imminent risk of preterm delivery in order to protect the brain of the premature infant. Previous research has shown that magnesium sulfate decreases the risk of cerebral palsy by ~30% in infants born preterm. Despite this, the dosage required for optimal neuroprotection remains unknown. We aimed to investigate whether 6 g magnesium sulfate given as a single bolus dose was tolerable for the women and infants and whether the desired target concentration in the mother's blood was reached and non‐toxic level in the infant could be ensured.    Material and methods  In total, 49 women who were at risk of delivery prior to 32 weeks of gestation were recruited. They received a bolus dose of 6 g magnesium sulfate intravenously between 1 and 24 h prior to giving birth and were closely monitored during and after infusion. Blood samples from the patients were analyzed at different time‐points (20–30 min after start of infusion, 1, 2, 6 and 24 h) post‐administration. Blood samples from the umbilical cord were also taken directly after birth to assess the concentration of magnesium in the infant.    Results  None of the women who received magnesium sulfate reached serum magnesium concentrations &gt;3.3 mmol/L. In all, 72% of the women showed serum magnesium levels within the therapeutic interval (2.0–3.5 mmol/L) and no adverse events were observed during the infusion. The serum magnesium levels in the mothers declined to pre‐bolus‐levels within 24 h after delivery. Serum magnesium levels in the umbilical cord samples ranged from 0.87 to 1.4 mmol/L, which means that all but two were within the normal expected range for a newborn premature infant.    Conclusions  A bolus dose of 6 g magnesium sulfate was well tolerated and without any serious side effects in either mother or infant. Most of our women reached the targeted concentration range of serum magnesium levels after infusion was completed. Their infants had magnesium levels within acceptable levels, regardless of gestational week or mother's body mass index.

acta obstetricia et gynecologica scandinavica

Maternal and fetal serum concentrations of magnesium after administration of a 6‐g bolus dose of magnesium sulfate ( MgSO 4  ) to women with imminent preterm delivery